Pilatus Biosciences doses first Hong Kong patient in PLT012 liver cancer trial
Pilatus Biosciences has dosed its first patient in Hong Kong in the ongoing Phase 1 study of PLT012, an investigational CD36-targeting antibody for advanced cancers. The new hepatocellular carcinoma cohort will examine safety, early clinical activity and biomarkers associated with tumor metabolism and immune suppression.